SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers...
Main Authors: | Yibo Xue, Brian Meehan, Zheng Fu, Xue Qing D. Wang, Pierre Olivier Fiset, Ralf Rieker, Cameron Levins, Tim Kong, Xianbing Zhu, Geneviève Morin, Lashanda Skerritt, Esther Herpel, Sriram Venneti, Daniel Martinez, Alexander R. Judkins, Sungmi Jung, Sophie Camilleri-Broet, Anne V. Gonzalez, Marie-Christine Guiot, William W. Lockwood, Jonathan D. Spicer, Abbas Agaimy, William A. Pastor, Josée Dostie, Janusz Rak, William D. Foulkes, Sidong Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-08380-1 |
Similar Items
-
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
by: Yibo Xue, et al.
Published: (2021-09-01) -
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
by: Yibo Xue, et al.
Published: (2019-02-01) -
SMARCA4-Deficient Carcinoma of Unknown Primary Presenting with Fatal Paraneoplastic Hypercalcemia in a Heart Transplant Recipient: First Report in a Male Patient
by: Abbas Agaimy, et al.
Published: (2017-01-01) -
Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review
by: Huanli Duan, et al.
Published: (2021-04-01) -
The genetic polymorphisms of ZC3HC1 and SMARCA4 are associated with hypertension risk
by: Huijun Ma, et al.
Published: (2019-11-01)